Mimedx (MDXG) Common Equity (2010 - 2026)

Mimedx has disclosed Common Equity across 17 years of filings, most recently posting $216.0 million for Q2 2026.

• In Q2 2026, Common Equity changed 0.29% year-over-year to $216.0 million; the TTM figure through Jun 2026 stood at $216.0 million (changed 0.29% YoY), while the FY2025 annual figure was $256.5 million, up 2.62% from the prior year.
• Common Equity came in at $216.0 million for Q2 2026 at Mimedx, down from $242.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $256.5 million in Q4 2025 to a low of -$18.0 million in Q4 2022.
• Average Common Equity over 5 years is $151.6 million, with a median of $187.5 million recorded in 2022.
• Year-over-year, Common Equity sank 22036.59% in 2022 and soared 13509.62% in 2024.
• Over 5 years, Common Equity stood at -$18.0 million in 2022, then soared by 893.4% to $142.7 million in 2023, then surged by 35.31% to $193.1 million in 2024, then soared by 32.85% to $256.5 million in 2025, then fell by 15.8% to $216.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $216.0 million in Q2 2026, $242.9 million in Q1 2026, and $256.5 million in Q4 2025.